Acasti Pharma Price to Book Ratio 2014-2024 | GRCE
Historical price to book ratio values for Acasti Pharma (GRCE) over the last 10 years. The current price to book ratio for Acasti Pharma as of October 29, 2024 is 0.55.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Acasti Pharma Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2024-10-28 |
3.21 |
|
0.55 |
| 2024-06-30 |
2.92 |
$5.85 |
0.50 |
| 2024-03-31 |
3.43 |
$6.57 |
0.52 |
| 2023-12-31 |
2.89 |
$6.88 |
0.42 |
| 2023-09-30 |
2.78 |
$7.10 |
0.39 |
| 2023-06-30 |
3.15 |
$8.61 |
0.37 |
| 2023-03-31 |
2.76 |
$9.14 |
0.30 |
| 2022-12-31 |
3.01 |
$13.01 |
0.23 |
| 2022-09-30 |
3.50 |
$13.47 |
0.26 |
| 2022-06-30 |
5.15 |
$14.08 |
0.37 |
| 2022-03-31 |
7.32 |
$14.67 |
0.50 |
| 2021-12-31 |
7.56 |
$15.04 |
0.50 |
| 2021-09-30 |
12.00 |
$15.47 |
0.78 |
| 2021-06-30 |
26.95 |
$12.31 |
2.19 |
| 2021-03-31 |
28.80 |
$12.82 |
2.25 |
| 2020-12-31 |
15.60 |
$7.91 |
1.97 |
| 2020-09-30 |
9.61 |
$4.40 |
2.19 |
| 2020-06-30 |
22.52 |
$5.73 |
3.93 |
| 2020-03-31 |
18.22 |
$6.91 |
2.64 |
| 2019-12-31 |
117.60 |
$-2.52 |
-46.61 |
| 2019-09-30 |
90.72 |
$-0.71 |
-127.29 |
| 2019-06-30 |
54.72 |
$1.62 |
33.80 |
| 2019-03-31 |
48.96 |
$6.78 |
7.22 |
| 2018-12-31 |
39.93 |
$14.22 |
2.81 |
| 2018-09-30 |
61.92 |
$-14.85 |
-4.17 |
| 2018-06-30 |
27.36 |
$7.66 |
3.57 |
| 2018-03-31 |
48.96 |
$12.01 |
4.08 |
| 2017-12-31 |
45.25 |
$22.70 |
1.99 |
| 2017-09-30 |
68.16 |
$38.47 |
1.77 |
| 2017-06-30 |
63.36 |
$46.04 |
1.38 |
| 2017-02-28 |
60.00 |
$55.72 |
1.08 |
| 2016-11-30 |
67.20 |
$66.75 |
1.01 |
| 2016-08-31 |
63.84 |
$76.00 |
0.84 |
| 2016-05-31 |
72.00 |
$83.16 |
0.87 |
| 2016-03-31 |
72.96 |
|
0.00 |
| 2016-02-29 |
72.00 |
|
0.00 |
| 2015-12-31 |
122.40 |
|
0.00 |
| 2015-09-30 |
129.07 |
|
0.00 |
| 2015-06-30 |
151.20 |
|
0.00 |
| 2015-03-31 |
230.16 |
|
0.00 |
| 2014-12-31 |
240.00 |
|
0.00 |
| 2014-09-30 |
369.60 |
|
0.00 |
| 2014-06-30 |
489.60 |
|
0.00 |
| 2013-09-30 |
1137.60 |
|
0.00 |
| 2013-06-30 |
1358.40 |
|
0.00 |
| 2013-03-31 |
1022.40 |
|
0.00 |
| 2014-03-31 |
551.66 |
|
0.00 |
| 2014-02-28 |
609.60 |
|
0.00 |
| 2013-12-31 |
600.00 |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
